In a regulatory filing, Gilead (GILD) Sciences disclosed that on October 6, Gilead announced that it has entered into settlement agreements to resolve the patent litigations with Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd., generic manufacturers that filed abbreviated new drug applications with the U.S. Food and Drug Administration to market generic versions of Biktarvy. Under the agreements, which are subject to standard acceleration provisions, no generic entry is expected prior to April 1, 2036 in the United States for Biktarvy tablets containing bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg, the filing stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating
- Gilead Sciences: Strong Growth Potential Driven by Yeztugo Launch and Strategic Positioning
- RBC sees 5% downside for Gilead if Trump referred to Biktarvy
- Bristol Myers commitment a reminder of Veeva’s progress, says Stifel
- Optimistic Growth Outlook for Gilead Sciences Driven by Yeztugo’s Market Potential and CDC Endorsement